GLPwatch
Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.
J Comp Eff Res · 2018
Last updated 2026-05-28In a study of 2,213 adults with Type 2 diabetes, those taking albiglutide or liraglutide showed similar improvements in blood sugar control, with an average 1.0% reduction in HbA levels after treatment. At 6 months, patients on albiglutide had slightly better medication adherence (69% vs. 64%) and were less likely to stop treatment (33.2% vs. 37.8%), but these differences were not significant at 12 months.
AI summary of the abstract below.
| Journal | J Comp Eff Res, 2018 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.20 |
| NIH percentile | 13 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
AIM: To compare medication adherence, discontinuation and glycemic control in patients receiving albiglutide versus liraglutide.
PATIENTS & METHODS: Administrative claims data and glycated hemoglobin (HbA) results were analyzed from a sample of adult health plan members with Type 2 diabetes.
RESULTS: Patients were matched 1:1 in the albiglutide (n = 2213) and liraglutide (n = 2213) overall cohorts and in 244 patients with HbA results from each treatment group. Mean HbA change from baseline was -1.0% for both groups. At 6 months, mean ± standard deviation adherence was 0.69 ± 0.29 versus 0.64 ± 0.29 (p < 0.001), and discontinuation was 33.2 versus 37.8% (p = 0.002) with albiglutide versus liraglutide, but these were not statistically or clinically different at 12 months.
CONCLUSION: Similar treatment patterns and clinically meaningful reductions in HbA were observed for both treatments in this real-world comparison.
Verbatim abstract via PubMed 28814107 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.